Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential
- 1 June 2017
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 25 (12) , 3018-3033
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016)Expert Opinion on Investigational Drugs, 2016
- Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19Journal of Medicinal Chemistry, 2016
- The Mediator complex: a central integrator of transcriptionNature Reviews Molecular Cell Biology, 2015
- Discovery of Potent, Orally Bioavailable, Small-Molecule Inhibitors of WNT Signaling from a Cell-Based Pathway ScreenJournal of Medicinal Chemistry, 2015
- Cyclin C is a haploinsufficient tumour suppressorNature Cell Biology, 2014
- The two faces of Cdk8, a positive/negative regulator of transcriptionBiochimie, 2014
- Identification of target genes for the CDK subunits of the Mediator complexGenes to Cells, 2011
- CDK8Transcription, 2010
- Cortistatin A is a High‐Affinity Ligand of Protein Kinases ROCK, CDK8, and CDK11Angewandte Chemie International Edition, 2009
- CDK8 is a colorectal cancer oncogene that regulates β-catenin activityNature, 2008